First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Ítems similars

• EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
  per: Dong, Kai, et al.
  Publicat: (2019)
• Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
  per: Chen, Ya, et al.
  Publicat: (2021)
• Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
  per: Wen, Miaomiao, et al.
  Publicat: (2018)
• Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
  per: Imamura, Fumio, et al.
  Publicat: (2020)
• First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
  per: Xu, Qinghua, et al.
  Publicat: (2019)